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Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental disease characterized by difficulties in social
communication, unusually restricted, repetitive behavior and interests, and specific abnormalities in language and
perception. The precise etiology of ASD is still unknown and probably heterogeneous. In a subgroup of patients, toxic
environmental exposure might lead to an imbalance between oxidative stress and anti-oxidant systems. Previous serum
and postmortem studies measuring levels of glutathione (GSH), the main cellular free radical scavenger in the brain,
have supported the hypothesis that this compound might play a role in the pathophysiology of autism.
Methods: Using the method of single-voxel proton magnetic resonance spectroscopy (MRS), we analyzed the GSH
signal in the dorsal anterior cingulate cortex (dACC) and the dorsolateral prefrontal cortex (DLPFC) of 24 ASD patients
with normal or above average IQs and 18 matched control subjects. We hypothesized that we would find decreased
GSH concentrations in both regions.
Results: We did not find overall group differences in neurometabolites including GSH, neither in the dorsal ACC (Wilks’
lambda test; p = 0.429) nor in the DLPFC (p = 0.288). In the dACC, we found a trend for decreased GSH signals in ASD
patients (p = 0.076).
Conclusions: We were unable to confirm our working hypothesis regarding decreased GSH concentrations in the ASD
group. Further studies combining MRS, serum, and cerebrospinal fluid measurements of GSH metabolism including
other regions of interest or even whole brain spectroscopy are needed.
Keywords: Autism spectrum disorder, Asperger syndrome, MR spectroscopy, Glutathione, Anterior cingulate cortex,
DLPFC
Background
Autism spectrum disorder (ASD)
ASD is a neurodevelopmental disorder characterized by dif-
ficulties in social communication and unusually restricted,
repetitive behavior and interests with a strong desire for
routines [1, 2]. In addition, there are specific abnormalities
in language, sensory, and social perception [2]. ASD is an
etiologically and phenotypically heterogeneous disorder [3].
In daily clinical practice, phenotypes with subnormal and
normal/above average intelligence are distinguished [2, 4].
While the International Classification of Diseases, tenth
edition (ICD-10) distinguishes childhood autism (F84.0),
atypical autism (F84.1), and Asperger syndrome (ICD-10
F84.5) (www.dimdi.de/static/de/klassi/icd-10-gm/kodesuch
e/onlinefassungen/htmlgm2015/block-f80-f89.htm), in the
current fifth version of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5), these categories are
summarized into a single category called ASD (299.00)
(www.dsm5.org). Prevalence figures for ASD vary between
1 and 2%, with increased incidence in males [5, 6]. ASD is
associated with high prevalence rates of comorbid classical
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psychiatric disorders such as depression, anxiety, attention
deficit hyperactivity disorder (ADHD), psychotic symptoms,
or emotionally unstable syndromes [7, 8]. The increasing
importance of ASD is caused by the high prevalence rates,
the fact that ASD is a life-long condition, and the high rates
of psychiatric comorbidity [2].
GSH and etiology of ASD
The precise etiology of ASD is still unknown and prob-
ably heterogeneous [1, 2, 9, 10]. Genetic aspects play a
certain role in ASD [2, 11]. Moreover, ASD may develop
as a consequence of acquired central nervous system
diseases, such as traumatic brain injury with epilepsy or
encephalitis [2, 4]. We earlier suggested an excitatory/in-
hibitory imbalance. Following this hypothesis, a
disturbed equilibrium between the most important exci-
tatory neurotransmitter glutamate and the most import-
ant inhibitory transmitter γ-amino-butyric acid (GABA)
might destabilize cortical networks, which in turn are
related to autistic symptoms [9,10]. Another patho-
physiological hypothesis of autism holds that an imbal-
ance between oxidative stress and antioxidant systems
(in particular glutathione [GSH], the main cellular free
radical scavenger in the brain), triggered by toxic envir-
onmental exposures, might play a central role in autism.
The so-called redox/methylation hypothesis is able to
bring different findings in ASD together (“A ‘unified field
theory’ of autism”) [12]. An imbalance between oxidative
stress and antioxidant systems might be triggered by
toxic environmental exposures such as to heavy metals
and xenobiotics. It is assumed that such an imbalance
might lead to neuronal damage in genetically predis-
posed individuals [13–15]. Similar pathophysiological
models have been discussed for schizophrenia [16]. Such
theories for ASD have been supported by laboratory and
postmortem findings of altered GSH concentrations in
ASD patients. GSH is the brain’s dominant antioxidant,
showing decreased blood levels of reduced GSH and in-
creased concentrations of oxidized glutathione (GSSG)
in the ASD group compared to controls on a meta-
analytical level [14]. Postmortem studies found a dis-
turbed redox ratio as a marker of oxidative stress in the
cerebellum and temporal cortex [3, 17].
The antioxidant glutathione (GSH)
GSH is the main cellular free radical scavenger in the brain,
playing a key role in protecting cells from exogenous and
endogenous toxins, particularly in the brain [3, 14]. It is a
tripeptide consisting of glutamate, cysteine, and glycine (L-
c-glutamyl-L-cysteinylglycine). Cysteine is the rate-limiting
amino acid for the synthesis of GSH [14]. It changes be-
tween the reduced monomeric (GSH) and oxidized dimeric
forms (GSSG) in the scavenging process [16, 18]. The
GSH/GSSG relation is an indicator of cellular redox status
[19]. In the healthy brains, the ratio of GSH/GSSG is over
100 [20, 21] and GSSG is normally below MRS detection
levels. GSH is essential for the synthesis and degradation of
proteins and the formation of the deoxyribonucleotide
precursors of DNA. It protects the cell against reactive oxy-
gen compounds and conjugates with foreign compounds. It
is also a cofactor in several other reactions [21].
Magnetic resonance spectroscopy (MRS) as a tool for
assessing GSH levels in vivo
MRS is a unique, non-invasive, and non-radioactive
method of measuring different neurometabolites. For ASD
research, MRS is of great interest because it is the only
method for the non-invasive measurement of the main
antioxidant, GSH, and of the major excitatory (glutamate,
Glu) and inhibitory (γ-aminobutyric acid, GABA) transmit-
ters in the human brain. In this study, we used the single-
voxel proton MRS technique, which enables metabolite
quantification in a predetermined volume of interest (VOI)
with internal water reference scaling. Moreover, MRS is
able to quantify additional neurometabolites, including
creatine (Cre), which is a marker of the brain’s energy
metabolism; choline (Cho) compounds or total-choline (t-
Cho), which are markers of membrane/phospholipid turn-
over and white/gray matter differences; N-acetylaspartate
(NAA), a marker of neuronal and axonal integrity; and
myo-inositol (mI), an organic osmolyte and second messen-
ger [21, 22].
Methodological MRS aspects
For the detection and quantification of GSH, various
more or less sophisticated MRS methods have been
applied. As apart from GSH, other important brain
metabolites were to be detected and quantified in our
study; we used short-TE PRESS (echo time-point-
resolved spectroscopy) for good overall signal-to-noise
ratio (SNR) and acceptable scan durations. Short-TE
PRESS has been validated for GSH quantification with
phantom experiments by others [23] and has been ap-
plied in clinical studies for voxel locations, which are
similar to ours [24] or closer to the sinuses and thus
even more challenging in terms of spectral quality [23].
MEGA-PRESS (Meshcher Garwood-PRESS), which has
been established as a gold standard for GABA detection,
has also been proposed for GSH editing. However, a
good editing efficiency requires long echo times (TE ≈
120 ms [25]), for which the rather short T2 of GSH (T2
= 67 ms at 4T [26]) gives rise to considerable signal loss
compared to short-TE PRESS. 2D MRS methods such as
JPRESS (J-resolved pointe-resolved spectroscopy) or
COSY (correlation spectroscopy) have also been pro-
posed for GSH detection. However, the 2D-fitting
methods required for quantification of these spectra still
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lack the robustness of the established linear combination
of a model spectra (LCModel) algorithm.
Previous MRS findings in the prefrontal cortex
Only one study analyzing GSH concentrations in ASD
has been published to date. Durieux et al. [24] found no
GSH signal differences between male ASD patients and
age- and IQ-matched controls in the basal ganglia and
the dorsomedial prefrontal cortex (DMPFC). Several
schizophrenia studies have been performed with mixed
results: In the largest study in first-episode schizophrenic
patients, 22% higher medial temporal lobe GSH concen-
trations were found compared to the control group [27].
However, two other studies analyzing prefrontal regions
showed no group differences between the schizophrenia
and healthy control groups [28, 29]. Studies analyzing
the established neurometabolites in ASD have mainly fo-
cused on the anterior cingulate cortex (ACC). Most of
these studies found abnormal glutamate concentrations
[9, 10, 30–32]. Cochran et al. [33] found higher glutam-
ine (Gln) levels and lower GABA/Cre levels in ASD,
supporting the idea of an excitatory (Glu)/inhibitory
(GABA) imbalance hypothesis. Anterior cingulate NAA,
t-Cho, Cre, and mI signals were also found to be altered
in some earlier studies [9, 10, 31, 34–37]. In the left
dorsolateral prefrontal cortex (DLPFC), low NAA/Cre
levels were found in the study by Fujii and colleagues
[36], but no significant differences were found in two
other studies [34, 38].
Rationale of our study
The main aim of this study was to compare GSH signals
in high-functioning ASD patients with normal and above
average intelligence quotients (IQ >90) and those in
healthy controls. We excluded patients with subnormal
IQs because of their possible link to syndromal and
secondary forms of autism. We decided to analyze the
dorsal ACC because of the recently reported neuro-
chemical abnormalities in this region [9, 10]. In addition,
we analyzed the DLPFC, which is an important part of
the dorsolateral prefrontal circuits [39]. Alterations in
these circuits lead to executive dysfunction [39]. The
DLPFC is also associated with deficits in theory of mind
[38, 40]. Neurochemical alterations in the DLPFC were
described earlier [9]. Based on the evidence from several
laboratory and postmortem studies [3, 14, 17], we
hypothesized that we would find decreased GSH
concentrations in the dACC and DLPFC of ASD
patients. Moreover, the study examined Cre, t-Cho, Glx
= Glu + Gln, NAA, and mI signals. On the basis of earl-
ier studies suggesting an excitatory-inhibitory imbalance
mechanism [9, 10], we hypothesized that we would find
altered Glx levels in the ACC.
Methods
All patients were recruited at the Freiburg Center for the
Diagnosis and Treatment of Autism (University Center
for Autism Spectrum, Universitäres Zentrum Autismus




The diagnostic process followed the National Institute
for Health and Clinical Excellence (NICE) guidelines for
adult autism (http://guidance.nice.org.uk/CG142/NICE-
Guidance/pdf/English). Only patients fulfilling the ICD-
10 F84.5 and DSM-IV 299.00 criteria were included. The
structured diagnostic procedure was performed by a
multiprofessional diagnostic team with three experi-
enced senior consultant psychiatrists and two fully quali-
fied senior psychologists. Anamnesis was conducted
over several sessions and included questioning of care-
givers or relatives (parents, siblings, partners, etc.) and
behavioral observations. The diagnosis was made by all
persons involved in the diagnostic process, incorporating
at least two experienced consultant psychiatrists or
psychologists. Psychometric assessments using the
autism-spectrum quotient (AQ) [41], empathy quotient
(EQ) [42], Australian Scale of Asperger’s Syndrome [43],
Social Responsiveness Scale [44], Bermond-Vorst Alex-
ithymia Questionnaire [45], and Adult Asperger Assess-
ment [46] were included in the diagnostic process. The
Wender Utah Rating Scale (WURS-k) [47] for ADHD
symptoms and the Beck Depression Inventory score
(BDI) [48] for depressiveness were collected to assess
the most frequent comorbidity and to control for influ-
ences of their symptoms on metabolic signals. General
crystalline intelligence was assessed using the multiple-
choice word test B (MWT-B) [49]. In unclear cases, the
Autism Diagnostic Interview-Revised [50], the autism
diagnostic observation schedule-generic [51], and/or
behavioral assessments as an in-patient were additionally
included. To avoid a heterogeneous study sample, we
excluded secondary and obviously syndromal forms of
ASD and only included patients with normal or above
average IQ.
Healthy control group
The control group was comprised of age-, IQ-, and
gender-matched healthy subjects. Controls with relevant
medical, psychiatric, or neurological diseases were
excluded from the study. All controls were assessed with
the AQ, EQ, WURS-k, BDI, and MWT-B questionnaires.
AQ scores > 30, EQ scores ≤ 30, WURS-k scores > 30,
BDI scores > 18, and IQ scores < 90 led to exclusion
from the study.
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MRS procedure
All measurements were performed at the University of
Freiburg on a 3 Tesla Siemens Magnetom TIM Trio
system (Erlangen, Germany). For signal reception, a
32-channel head coil was used. First, a standard
magnetization-prepared rapid gradient echo (MPRAGE)
T1-weighted anatomical scan was recorded with the
following parameters: field of view (FOV) = 256 ×
256 mm2, repetition time (TR) = 2200 ms, TE = 4.11 ms,
flip angle = 12°, and voxel size = 1 × 1 × 1 mm3. Spectro-
scopic measurements were performed in the dorsal
anterior cingulate cortex (30 × 20 × 25 mm; 15.0 mL)
and in the left dorsolateral prefrontal cortex (25 × 25 ×
25 mm; 15.6 mL) using a PRESS sequence with a TR of
1500 ms, a TE of 30 ms, and a number of slices of 256.
The PRESS sequence used in this work contained
Hamming-filtered sinc pulses with a bandwidth of
3365 Hz for excitation and Mao pulses with a bandwidth
of 1153 Hz for refocusing. The signal readout consisted
of 1024 sampling points covering a bandwidth of
1200 Hz. For metabolite quantification with the internal
water reference method, a water spectrum was acquired
using the same protocol as for the acquisition of the
actual spectra, but the radio frequency pulses for water
suppression were switched off, and the number of
spectral averages was reduced to 16 [52]. For spectral
fitting and quantification, the well-established and validated
LCModel algorithm was applied (http://s-provencher.com/
lcmodel.shtml). The metabolite basis set for LCModel
quantification was simulated numerically with Matlab,
using chemical shifts and coupling constants derived from
the literature, and fully shaped RF waveforms of the slice-
selective refocusing pulses as employed by the scanner [53].
For spectroscopic analyses, only spectra with Cramér-Rao
lower bounds (CRLBs) smaller than 20% for the main
metabolites were included [54, 55]. Finally, the 3D
MPRAGE datasets were segmented into gray matter (GM),
white matter (WM), and cerebrospinal fluid (CSF),
using a unified segmentation approach [56] imple-
mented in Statistical Parametric Mapping, Version 8 (SPM8;
www.fil.ion.ucl.ac.uk/spm/software/spm8). For each VOI, the
partial volumes of GM, WM, and CSF were com-
puted from this segmentation. These partial volumes
were used for estimation of the water content in the
VOI, which was needed for quantification and for
metabolite concentration correction, assuming that
the measured brain metabolites are only contained in
GM and WM, but not in CSF [9, 10, 56, 57] (Figs. 1
and 2).
Study sample
Table 1 gives an overview of the study sample. In the
ASD group, only one patient had to be excluded due to
technical reasons; in the control sample, we excluded
five subjects because of suprathreshold psychometric
findings and one control due to technical reasons.
Statistical analyses
Spectroscopic, demographic, and psychometric data
were transferred to a Statistical Package for the Social
Sciences (SPSS inc., Stanford USA) database. For group
comparisons of continuous variables (age, nicotine
consumption, psychometric scores), we performed two-
sided independent sample t tests. For group comparisons
of gender, we calculated Pearson’s two-sided chi squared
test. The neurometabolite concentrations in the dACC
and DLPFC of the ASD and control groups were
compared using a multivariate analysis of covariance
(MANCOVA) and employing a general linear model.
The factor group was chosen as the fixed factor and the
neurometabolites (GSH, Cre, t-Cho, Glx, NAA, and mI)
as dependent variables. No covariates were included in
the first MANCOVA. The possible confounding factors
of age [58], IQ [59], gender [60, 61], and nicotine
consumption [62, 63] did not differ between the groups.
Therefore, we did not include these variables as covari-
ates in the main analyses (as we did in earlier studies
[57]). However, we performed another analysis with age,
IQ, and nicotine consumption as covariates to exclude
effects due to within-subject variations in these parame-
ters. To test for an overall group effect across all six
neurometabolites, a multivariate Wilks’ lambda test was
Fig. 1 Voxel localization in the dorsal anterior cingulate cortex in both sides (two images on the left) and in the left dorsolateral prefrontal cortex (two
images on the right)
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used in both cases. When comparing medicated and un-
medicated ASD patients, we found significant differences
in the gender ratio; therefore, we also included gender
(besides group [medicated vs. unmedicated]) as a fixed
variable in the respective MANCOVA. Correlation
analyses were performed using the Pearson correlation
coefficient. To test for the influence of age on the correl-
ation between GSH and IQ, we performed a partial
correlation, adjusted for age. For overall and single-
group differences in neurometabolite signals, the level of
significance was corrected for multiple tests using the
Bonferroni approach (p < 0.025 due to performing the
measurements in two independent regions). The same
significance level of p < 0.025 was used for the correl-
ation analyses (because of the two measured regions),
and for all other calculations, a p value <0.05 served as
the criterion of significance.
Results
Demographic and psychometric data
The ASD and control groups did not differ significantly
in age, IQ, nicotine consumption, and gender. The age
range varied from 25 to 57 years in the ASD group and
from 24 to 60 years in the control sample. Table 2 also
gives detailed information about levels of psychometric
scores, as well as education and occupational situation
for all participants.
MRS results
We acquired robust data with high SNR (40.452 ±
27.974 for the ACC VOI and 39.0 ± 21.462 for the
DLPFC voxel) and low average CRLBs for GSH (6.4% for
the ACC voxel and 7.0% for the DLPFC voxel). Using a
multivariate analysis of covariance, significant group dif-
ferences were found neither in the dACC (Wilks’ lambda
test without covariates p = 0.429, with covariates p =
0.564) nor in the DLPFC (without covariates p = 0.288,
with covariates p = 0.262; Table 3).
GSH
On the level of single metabolite concentrations, there
were tendencies for decreased anterior cingulate GSH
levels in the ASD group (ASD group, 1.79 mM± 0.37;
control group, 1.98 mM± 0.26; p = 0.076) that were not
stable in the MANCOVA analyses with potential influ-
encing factors as covariates (p = 0.147).
Other neurometabolites
The anterior cingulate mI signals were also lower in the
ASD group (5.82 mM± 0.74 to 6.31 mM± 0.47; p =
0.018). Cre concentrations in the ASD sample were
lower in the dACC region (7.49 ± 0.92 to 7.97 ± 0.39; p =
0.048) and higher in the DLPFC VOI (6.91 ± 0.34 to
6.63 ± 0.35; p = 0.013).
Analysis of dimensional associations
GSH
The correlation analysis for the ASD sample (N = 24) in
the dACC VOI revealed a significant negative correl-
ation between the GSH signal and IQ (r = −0.549; p =
0.005, N = 24) and age (r = −0.567, p = 0.004, N = 24);
Fig. 2 MR-spectrum from the dorsal anterior cingulate cortex (left) and in the left dorsolateral prefrontal cortex (dACC; right). In the middle, we
present glutathione fitting in a patient spectrum from the dACC. GSH glutathione, mI myo-inositol, t-Cho phosphorylcholine + glycerylphosphoryl-
choline, Cre creatine, Glx glutamate + glutamine, NAA N-acetylaspartate
Table 1 Autism spectrum disorder and healthy control samples




Included subjects 25 24
Technical reasons for
further exclusion
1 × bad spectral
quality
1 × bad spectral
quality
Post hoc information about
psychometric exclusion criteria
0 1× BDI-score >18,
1× WURS-k-score
>30, 2× EQ-score
≤30, 1× IQ <90
Number of spectra for statistical
analysis
24 18
BDI Beck Depression Inventory score, WURS-k Wender Utah Rating Scale, EQ
empathy quotient, IQ intelligence quotient
Endres et al. Molecular Autism  (2017) 8:10 Page 5 of 11
however, a partial correlation for GSH and IQ—cor-
rected for age—was not significant (r = −0.290; df = 21; p
= 0.179, N = 24).
Other neurometabolites
In addition, we found a highly significant negative cor-
relation between age and the Glx signal in the DLFC (r
= −0.730, p = <0001, N = 24) (Table 4).
Medication effects
Finally, we compared medicated (n = 13) and unmedi-
cated ASD patients (n = 11). Both groups showed no
significant differences in the possibly confounding
factors of age, IQ, and nicotine consumption. Since they
differed in gender ratio, we performed a MANCOVA
with the fixed variables of medication and gender. For
both VOIs, we found no significant group differences
(Wilks’ lambda test, p = 0.891 for the dACC and p =
0.484 for the DLPFC).
Discussion
The main finding of this study is the absence of signifi-
cant group differences in the dACC or in the DLPFC
with respect to GSH. Therefore, we were not able to
confirm our working hypothesis regarding decreased
GSH concentrations in the ASD group.
Limitations
First, potential limitations should be considered. The
diagnostic procedure was performed by an experienced,
multiprofessional diagnostic team following the NICE
guidelines for adult autism. To avoid a heterogeneous
study sample, we included only patients with normal or
above average IQs. Therefore, our cohort is not repre-
sentative for low-functioning autism. The advanced age
of our patients should also be considered. Because ASD
is a neurodevelopmental disorder, the GSH metabolism
could have normalized over the years. The sample size is
comparable with other studies analyzing GSH metabol-
ism [24, 27]. One limitation is that we analyzed patients
with and without medication. Therefore, our results
Table 2 Demographic and psychometric information for the autism spectrum disorder and control groups
ASD (n = 24) Controls (n = 18) Statistics
Age 40.54 ± 10.279 37.17 ± 10.983 p = 0.313
Intelligence quotient 114.29 ± 15.213 113.00 ± 13.920 p = 0.779
Gender 12 m:12 f 8 m:10 f p = 0.721
Nicotine 2.292 ± 5.894 2.222 ± 6.691 p = 0.972
Autism-spectrum quotient 39.08 ± 6.386 12.94 ± 5.504 p < 0.001
Empathy quotient 17.38 ± 9.523 47.94 ± 9.710 p < 0.001
Wender Utah Rating Scale 33.75 ± 16.690 8.72 ± 7.954 p < 0.001
Beck Depression Inventory score 17.25 ± 12.365 3.22 ± 4.236 p < 0.001
Level of education Low school degree, 1 (4.2%) Low school degree, 0 (0%)
Medium school degree, 3 (12.5%) Medium school degree, 3 (16.7%)
High school degree, 9 (37.5%) High school degree, 6 (33.3%)
University degree, 9 (37.5%) University degree, 9 (50%)
Other, 2 (8.3%) Other, 0 (0%)
Occupational situation Full-time employed, 13 (54.2%) Full-time employed, 7 (38.9%)
Part-time employment, 4 (16.7%) Part-time employment, 4 (22.2%)
In vocational training/studying, 1 (4.2%) In vocational training/studying, 7 (38.9%)
Pension, 1 (4.2%) Pension, 0 (0%)
Unemployed, 4 (16.7%) Unemployed, 0 (0%)
Other, 1 (4.2%) Other, 0 (0%)
Psychiatric medication
(in the last 3 months)
No, 11 No, 18
AD, 6 AD, 0
NL, 1 NL, 0
AD + NL, 5 AD + NL, 0
AD + MPH, 1 AD + MPH, 0
ASD autism spectrum disorder, IQ intelligence quotient, AD antidepressants, NL neuroleptics, MPH methylphenidate
For references, see text
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might be influenced by medication-induced oxidative
stress [64], and further studies should analyze unmedi-
cated patients. However, in our sample, we did not find
any significant differences in neurometabolite concentra-
tions between medicated and non-medicated patients.
We therefore do not assume a relevant medication effect
in our cohort.
For MRS measurements, we used the well-established
single-voxel 1H-MRS method (applying short-TE
PRESS). The accuracy of GSH detection with such
standard MRS methods is a strongly disputed topic in
the MRS community (see “Background” section). How-
ever, standard MRS sequences (PRESS and STEAM)
have previously been applied in a number of other GSH
studies in humans, and to date, there is no clear evi-
dence of better in vivo GSH quantification accuracy with
different editing methods such as MEGA-PRESS [23, 27,
65–67]. The measurement of GSH levels is complicated
due to significant resonance overlap with other metabo-
lites [21]. By using a 32-channel head coil at a field
strength of 3 T and the manual shimming procedure, we
obtained robust data with high SNR and low average
CRLBs for GSH. We were only able to measure GSH
signals. The GSH/GSSG ratio would have been a better
indicator of cellular redox status; however, the GSSG
concentration was below the MRS detection limit [68].
We used the established and stable SVS method, which
allows only the measurement of preselected VOIs.
Therefore, we were only able to measure the concentra-
tions of neurometabolites of interest in preselected VOIs
(dACC and DLPFC). Data exclusion was performed
based on the CRLBs determined by LCModel (rejection
for CRLBs >20% for the main metabolites). In psychi-
atric MRS studies, metabolite concentrations are often
reported as ratios to the Cre concentration, which is
considered to be relatively unaffected by most patho-
logical conditions. In our study, we performed metabol-
ite quantification with internal water reference scaling to
avoid bias arising from varying levels of Cre. In fact, we
did find a trend of decreased Cre signals in the dACC
and a tendency for Cre signals to be increased in the
DLPFC of patients, suggesting that metabolite quantifi-
cation is more robust than calculating ratios over Cre, as
in other ASD studies. The LCModel software allowed all
spectra to be treated the same.
Interpretation of our findings in the context of earlier
studies
This was the first study analyzing anterior cingulate
GSH signals, and we only found a tendency for de-
creased GSH concentrations. The only currently avail-
able study analyzing GSH concentrations in ASD found
no differences in the left basal ganglia and the left
DMPFC [24]. Therefore, our observation of normal GSH
concentrations in the DLPFC is compatible with the
negative findings of Durieux et al. [24] in the DMPFC.
In the region of the left DLPFC, two other studies also
failed to detect any metabolic changes [34, 38]. We
found decreased levels of Glx in the dACC, however,
without reaching a level of significance, in contrast to
earlier studies in the pregenual ACC, where a significant
Glx decrease was observed [9, 10, 30]. In other studies,
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covariatesa (Wilks’
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MANCOVA with
covariatesa (Wilks’









GSH 1.7939 1.9810 p = 0.076 p = 0.147 1.6017 1.6247 p = 0.706 p = 0.655
0.37068 0.26364 0.18921 0.19985
Cre 7.4948 7.9657 p = 0.048 p = 0.082 6.9109 6.6330 p = 0.013 p = 0.020
0.91646 0.39453 0.33509 0.35355
t-Cho 1.8900 1.9926 p = 0.213 p = 0.200 1.8507 1.8289 p = 0.757 p = 0.984
0.27320 0.24132 0.18029 0.27268
Glx 11.7396 12.5834 p = 0.142 p = 0.272 9.4585 9.2360 p = 0.396 p = 0.094
2.14178 1.21151 0.97482 0.58407
NAA 8.1840 8.8939 p = 0.168 p = 0.319 8.8931 8.7972 p = 0.661 p = 0.423
1.82291 1.29632 0.75962 0.59745
mI 5.8211 6.3095 p = 0.018 p = 0.036 5.0549 4.9064 p = 0.344 p = 0.456
0.73532 0.46517 0.50464 0.48836
ASD autism spectrum disorder, MANCOVA multivariate analysis of covariance, p p value to test for differences between groups, GSH glutathione, Cre creatine, t-Cho
phosphorylcholine + glycerylphosphorylcholine, Glx glutamate + glutamine, NAA N-acetylaspartate, mI, myo-inositol
aAge, intelligence quotient, and nicotine consumption
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increased Glx levels were found in the ACC [31, 32],
suggesting fluctuating levels of glutamate. Similar pat-
terns of findings are reported in other neuropsychiatric
conditions like epilepsy or anti-N-methyl-D-aspartate-
receptor encephalitis [9, 69]. GSH and Glx metabolisms
are closely related: GSH is synthesized from Glu, cyst-
eine, and glycine [21]. Glutathione is a physiologic reser-
voir of neuronal Glu [70]. Glutamatergic metabolism
seems to play an important role in ASD, possibly related
to a cybernetic imbalance between neuronal excitation
and inhibition [9, 10]. Glu is the major excitatory neuro-
transmitter [71], and Gln is its precursor and storage
form in astrocytes [53]. Low-plasma Gln may deplete
GSH, because Gln provides Glu to synthesize glutathi-
one; GSH depletion may deplete Gln for the same
reason [12]. In their ASD meta-analysis, Frustraci et al.
found decreased blood levels of reduced glutathione
(27%) and increased concentrations of oxidized glutathi-
one (GSSG; 45%) relative to controls [14], suggesting a
role of redox imbalance in the pathogenesis of ASD.
Postmortem studies examining the temporal cortex and
the cerebellum showed decreased GSH/GSSG ratios as a
marker for oxidative stress [3, 17]. In the current study,
we were not able to detect significant group differences
in GSH signals between patient and control groups in
the dACC and the DLPFC. Our results might be influ-
enced by several factors such as medication (see “Limita-
tions” section). Therefore, the examination of further
regions, especially the temporal cortex and the cerebel-
lum (because of the earlier described alterations in post-
mortem studies) in medication-free ASD patients should
be performed. In addition, we found a trend for reduced
mI concentrations in the dACC. Reduced mI levels may
be associated with abnormal developmental processes
via abnormal astrocyte density or altered neuronal
growth [72], as shown in children with ASD [72, 73].
However, earlier findings are inconsistent [35, 72]. The
trend for alterations in the Cre signals might be associ-
ated with brain-region-specific altered energy metabol-
ism [22]. Decreased Cre signals, as observed in the
dACC, are in line with the research of Bejjani et al. [31].
A tendency for higher Cre concentrations in the ASD
group has not been described previously.
The dimensional analyses showed dACC GSH signal
to be linked to IQ and age but not to autistic symptoms.
We found a negative correlation between the GSH
signals in the dACC and the IQ scores; the association
between high IQ figures and low GSH levels is contrary
to earlier research, which assumed impairment in cogni-
tive function with reducing GSH levels [74]. Moreover,
dACC GSH signals in the ASD collective correlated
negatively with age; earlier studies also described an age-
dependent decline of GSH concentrations [21]. A partial
correlation between GSH and IQ, corrected for age, was
not significant.
Conclusions
We were not able to detect significant alteration in GSH
levels in the dACC and DLPFC of ASD patients. Signifi-
cantly decreased GSH levels were earlier reported in
blood and postmortem studies of the temporal cortex
and the cerebellum [17]. Further MRS studies should
focus on the temporal cortex and the cerebellum in
medication-free ASD patients. Moreover, we suggest a
combined blood and MRS measurement of GSH signals.
Whereas the MRS measurements allow regional meta-
bolic investigations in certain brain regions, blood
analyses would allow the determination of the whole
redox system by also measuring GSSG signals.
Table 4 Correlation analyses for the autism spectrum disorder
group (a p value of <0.025 served as the criterion of significance)
AQ EQ WURS-k BDI IQ Age
Anterior cingulate cortex (n = 24)
GSH 0.077 −0.193 0.287 −0.006 −0.549 −0.567
0.721 0.366 0.174 0.978 0.005 0.004
Cre 0.183 −0.373 −0.103 −0.082 −0.329 −0.310
0.393 0.072 0.632 0.702 0.117 0.140
t-Cho 0.286 −0.268 0.063 0.010 −0.106 −0.195
0.175 0.206 0.770 0.964 0.622 0.360
Glx 0.301 −0.394 0.104 −0.019 −0.370 −0.346
0.152 0.057 0.628 0.931 0.075 0.098
NAA 0.363 −0.399 −0.007 −0.102 −0.297 −0.310
0.081 0.053 0.974 0.634 0.159 0.140
mI −0.011 −0.040 −0.013 −0.057 −0.289 −0.339
0.959 0.853 0.952 0.793 0.171 0.105
Dorsolateral prefrontal cortex (n = 24)
GSH −0.014 −0.058 0.126 0.154 −0.020 −0.166
0.950 0.790 0.556 0.471 0.927 0.438
Cre 0.042 −0.176 −0.287 −0.283 −0.136 −0.115
0.847 0.410 0.173 0.180 0.527 0.593
t-Cho −0.226 0.443 −0.010 −0.027 0.434 0.097
0.289 0.030 0.964 0.901 0.034 0.653
Glx −0.079 0.162 0.312 −0.179 −0.454 −0.730
0.713 0.450 0.138 0.402 0.026 0.000
NAA −0.038 −0.297 0.183 0.033 −0.341 −0.391
0.861 0.159 0.391 0.880 0.103 0.059
mI −0.205 0.310 0.004 −0.349 0.005 0.035
0.336 0.141 0.987 0.094 0.982 0.870
Presented are the Pearson correlation coefficients (above) and p values (below)
Significant results are depicted in italics
AQ autism quotient, EQ empathy quotient, WURS Wender Utah Rating scale,
BDI Beck Depression Inventory score, IQ intelligence quotient, GSH glutathione,
Cre creatine, t-Cho phosphorylcholine + glycerylphosphorylcholine, Glx glutamate +
glutamine, NAA N-acetylaspartate,mImyo-inositol (for references, see text)
Endres et al. Molecular Autism  (2017) 8:10 Page 8 of 11
Moreover, CSF measurements of the GSH/GSSG ratios
could provide additional information [75]. The topic of
antioxidants is of high public interest and important for
patients because of the possible treatment options with
supplemental antioxidants (e.g., with N-acetylcysteine, a
GSH precursor) [18].
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